KR102955590B1 - 인간화 항-SIRPα 항체 - Google Patents

인간화 항-SIRPα 항체

Info

Publication number
KR102955590B1
KR102955590B1 KR1020217016769A KR20217016769A KR102955590B1 KR 102955590 B1 KR102955590 B1 KR 102955590B1 KR 1020217016769 A KR1020217016769 A KR 1020217016769A KR 20217016769 A KR20217016769 A KR 20217016769A KR 102955590 B1 KR102955590 B1 KR 102955590B1
Authority
KR
South Korea
Prior art keywords
ser
sirpα
antibody
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217016769A
Other languages
English (en)
Korean (ko)
Other versions
KR20210093270A (ko
Inventor
지스베르투스 프란시스커스 마리아 베헤이덴
Original Assignee
비온디스 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비온디스 비.브이. filed Critical 비온디스 비.브이.
Publication of KR20210093270A publication Critical patent/KR20210093270A/ko
Application granted granted Critical
Publication of KR102955590B1 publication Critical patent/KR102955590B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217016769A 2018-11-15 2019-11-15 인간화 항-SIRPα 항체 Active KR102955590B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18206594.6 2018-11-15
EP18206594 2018-11-15
PCT/EP2019/081523 WO2020099653A1 (en) 2018-11-15 2019-11-15 HUMANIZED ANTI-SIRPα ANTIBODIES

Publications (2)

Publication Number Publication Date
KR20210093270A KR20210093270A (ko) 2021-07-27
KR102955590B1 true KR102955590B1 (ko) 2026-04-21

Family

ID=64331834

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016769A Active KR102955590B1 (ko) 2018-11-15 2019-11-15 인간화 항-SIRPα 항체

Country Status (14)

Country Link
US (1) US12180295B2 (cg-RX-API-DMAC7.html)
EP (1) EP3880707A1 (cg-RX-API-DMAC7.html)
JP (1) JP7451520B2 (cg-RX-API-DMAC7.html)
KR (1) KR102955590B1 (cg-RX-API-DMAC7.html)
CN (1) CN113412279B (cg-RX-API-DMAC7.html)
AU (1) AU2019378101B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009275A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118966A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001260A1 (cg-RX-API-DMAC7.html)
IL (1) IL282756A (cg-RX-API-DMAC7.html)
MX (1) MX2021005761A (cg-RX-API-DMAC7.html)
MY (1) MY204673A (cg-RX-API-DMAC7.html)
SG (1) SG11202104431PA (cg-RX-API-DMAC7.html)
WO (1) WO2020099653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12018550160B1 (en) 2016-04-14 2024-07-03 Ose Immunotherapeutics NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110325549B (zh) 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
JP7160833B2 (ja) * 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
WO2019183266A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CR20200566A (es) 2018-05-25 2021-02-19 Alector Llc Anticuerpos anti-sirpa y metodos de utilización de los mismos
US20230414778A1 (en) * 2020-11-11 2023-12-28 Daiichi Sankyo Company, Limited COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPalpha ANTIBODY
CN112574310B (zh) * 2020-12-11 2023-05-05 浙江博锐生物制药有限公司 抗SIRPα抗体及其用途
CN114790241B (zh) * 2021-01-26 2024-12-13 北京免疫方舟医药科技有限公司 抗tigit抗体及其应用
AU2022284373A1 (en) * 2021-06-04 2024-01-04 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
TW202408584A (zh) * 2022-05-10 2024-03-01 日商第一三共股份有限公司 抗體-藥物結合物與抗SIRPα抗體之組合
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
EP1244707A1 (de) 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
PT2474557E (pt) 2007-07-16 2014-12-03 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗il−1rap抗体及びヒトを処置するためのそれらの使用
MX2013014789A (es) * 2011-06-16 2014-01-20 Novartis Ag Proteinas solubles para utilizarse como productos terapeuticos.
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
KR101674784B1 (ko) 2012-04-05 2016-11-09 에프. 호프만-라 로슈 아게 인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
RU2681994C2 (ru) * 2012-12-26 2019-03-14 Онкосинерджи, Инк. КОМПОЗИЦИИ АНТИТЕЛА К ИНТЕГРИНУ β1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
CN103665165B (zh) * 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
ES2751915T5 (es) * 2014-08-15 2022-12-23 Merck Patent Gmbh Proteínas de fusión de inmunoglobulina con SIRP alfa
DK3298043T3 (da) 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
DK4186927T3 (da) 2015-10-21 2025-06-10 Ose Immunotherapeutics Fremgangsmåder og sammensætninger til at ændre makrofagers polarisering til pro-inflammatoriske celler til behandling af kræft
EP3493845A4 (en) 2016-08-03 2020-04-15 The Board of Trustees of the Leland Stanford Junior University INTERRUPTION OF FC RECEPTOR USE ON MACROPHAGES TO IMPROVE THE EFFECTIVENESS OF ANTI-SIRPALPHA ANTIBODY THERAPY
JOP20190009A1 (ar) * 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN110325549B (zh) * 2016-12-09 2024-03-08 艾利妥 抗SIRPα抗体及其使用方法
PT3443010T (pt) * 2017-02-17 2024-10-21 Ose Immunotherapeutics Novos anticorpos anti-sirpa e suas aplicações terapêuticas
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー.ブイ. 抗sirpアルファ抗体
PT3625259T (pt) * 2017-05-16 2024-07-04 Synthon Biopharmaceuticals Bv Anticorpos anti-sirpalfa
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods

Also Published As

Publication number Publication date
WO2020099653A1 (en) 2020-05-22
AU2019378101B2 (en) 2025-10-16
CN113412279B (zh) 2024-09-24
US20210388107A1 (en) 2021-12-16
KR20210093270A (ko) 2021-07-27
JP2022509065A (ja) 2022-01-20
AU2019378101A1 (en) 2021-05-27
EP3880707A1 (en) 2021-09-22
JP7451520B2 (ja) 2024-03-18
BR112021009275A2 (pt) 2022-01-04
MY204673A (en) 2024-09-09
MX2021005761A (es) 2021-08-11
CL2021001260A1 (es) 2021-12-24
CN113412279A (zh) 2021-09-17
CA3118966A1 (en) 2020-05-22
SG11202104431PA (en) 2021-05-28
US12180295B2 (en) 2024-12-31
IL282756A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP7451520B2 (ja) ヒト化抗SIRPα抗体
US12258410B2 (en) Anti-SIRPα antibodies and methods of use thereof
US20230192847A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
US10973853B2 (en) Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereof
EP3625259B1 (en) Anti-sirpalpha antibodies
US20260098089A1 (en) Antagonist anti-cd7 antibodies
EP3988569A1 (en) Antibodies to pd-1 and uses thereof
US20250043003A1 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
JP2024515396A (ja) 抗cd47モノクローナル抗体及びその使用
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
US20240165227A1 (en) Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
JP2023513059A (ja) 抗ミューラー管ホルモン受容体2抗体及び使用方法
RU2812199C2 (ru) ГУМАНИЗИРОВАННЫЕ АНТИ-SIRPα АНТИТЕЛА
HK40128286A (zh) 使用抗ccr8抗体、化学疗法和免疫疗法组合的抗癌疗法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)